Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:37:36.221Z.
Calculation as of: 2026-10-06T14:37:36.221Z.
Quote observation: 2026-10-06T14:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Faeth Therapeutics, Inc.
Market Cap
$678.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$690.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$663.69M
Operating Cash Flow Yield
6.95%
TTM Avg
9.30%
3Y Avg
5.99%
5Y Avg
5.99%
Market Cap
$655.17M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$703.70M
Operating Cash Flow Yield
46.88%
TTM Avg
23.51%
3Y Avg
20.54%
5Y Avg
18.34%
Market Cap
$650.20M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$647.30M
Operating Cash Flow Yield
N/A
TTM Avg
2.08%
3Y Avg
1.21%
5Y Avg
1.21%
Market Cap
$712.45M
Operating Cash Flow Yield
N/A
TTM Avg
23.08%
3Y Avg
23.11%
5Y Avg
23.11%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $678.63M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $690.35M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $666.02M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $663.69M | 6.95% | 9.30% | 5.99% | 5.99% |
| Helus Pharma Inc. (HELP)vs › | $655.17M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $703.70M | 46.88% | 23.51% | 20.54% | 18.34% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $650.20M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $647.30M | N/A | 2.08% | 1.21% | 1.21% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $712.45M | N/A | 23.08% | 23.11% | 23.11% |
| Aura Biosciences, Inc. (AURA)vs › | $635.62M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
